Digital transformation key to managing rising organisational healthcare costs in India
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Development services for gene and cell therapies is planned to begin first in 2025
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Additionally, Rs. 12.85 crores shall be infused into the P H Diagnostic by way of either Equity or Loan to pay the existing debt
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lacosamide is indicated to treat partial-onset seizures
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Subscribe To Our Newsletter & Stay Updated